In vivo evaluation of the safety and efficacy of a novel chitosan gel in the reduction of adhesions following abdominal surgery in both animal and human models

体内评估新型壳聚糖凝胶在动物和人体模型中减少腹部手术后粘连的安全性和有效性

• 批准号: nhmrc : 1050883
• 负责人: A/Pr Stephen Moratti
• 金额: $ 35.48万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vivo-evaluation-safety-human-models/112185
• 关键词: vivo; evaluation; safety; efficacy; novel

Up to 95% of abdominal surgery patients will develop adhesions within the abdomen, with nearly 1 in 5 requiring hospital readmission for pain, reduced gastrointestinal function and bowel obstruction. Newly developed Chitodex gel has been shown to be effective in the control of bleeding and the reduction of adhesions following sinus surgery. These projects will now explore its use in abdominal surgery. Chitodex gel has the potential to benefit millions of patients each year and drastically lessen the burden on our health system.

高达95%的腹部手术患者会出现腹部粘连，近五分之一的患者因疼痛、胃肠功能下降和肠梗阻而需要再次住院。新开发的几丁糖凝胶已被证明在控制鼻窦手术后出血和减少粘连方面有效。这些项目现在将探索其在腹部外科中的应用。几丁糖凝胶每年有可能使数百万患者受益，并极大地减轻我们卫生系统的负担。